Arrowhead Pharmaceuticals Inc (ARWR)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$13.85
Buy
$13.88
$-0.87 (-5.91%)
Prices updated at 26 Mar 2025, 19:32 EDT
| Prices minimum 15 mins delay
Prices in USD
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 241m | 4m | |
| - | - | |
| -205m | -601m | |
| -85.16 | -16,927.06 | |
| -205m | -599m | |
| -176m | -562m | |
| Sales, General and administrative | 91m | 97m |
| Interest expenses | 18m | 32m |
| Provision for income taxes | 3m | -3m |
| Operating expenses | 446m | 605m |
| Income before taxes | -206m | -612m |
| Net income available to common shareholders | -205m | -599m |
| -2.77 | -5.15 | |
| Net interest income | -3m | -10m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -2.77 | -5.15 |
| Free cash flow per share | -3.0972 | -5.0451 |
| Book value/share | 2.5241 | 1.4768 |
| Debt equity ratio | 0.385519 | 2.718934 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 420m | 695m |
| Current liabilities | 105m | 103m |
| Total capital | 271m | 579m |
| Total debt | 115m | 511m |
| Total equity | 271m | 185m |
| Total non current liabilities | - | - |
| Loans | - | 393m |
| Total assets | 766m | 1,140m |
| Total liabilities | - | - |
| Cash and cash equivalents | 111m | 103m |
| Common stock | 107m | 124m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 108m | 111m |
| Cash dividends paid | - | - |
| -331m | -604m | |
| Investments (gains) losses | -96m | -420m |
| 111m | 103m | |
| Net income | - | - |
| -154m | -463m | |
| -177m | -141m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
